Reboxetine
Reboxetine is a selective norepinephrine reuptake inhibitor (SNRI) antidepressant used primarily to treat major depressive disorder. It works by increasing norepinephrine levels in the brain to help improve mood and emotional state. This medication is available in several countries outside the United States and is typically prescribed when other first-line treatments have not been effective.
Reboxetine is an SNRI antidepressant that increases norepinephrine levels to help treat major depressive disorder.
Key facts at a glance
- ATC
- N06AX18
- RxNorm
- 60842
- Generic
- Reboxetine
- Class
- atc-n06
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- oral
- Forms
- tablet
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Reboxetine is primarily prescribed for the treatment of major depressive disorder (MDD). It may be used when patients have not responded adequately to other antidepressant medications. In some regions, it is also used for anxiety associated with depression.
Reboxetine works as a selective norepinephrine reuptake inhibitor (SNRI), meaning it blocks the reabsorption (reuptake) of norepinephrine in the brain. By preventing this reuptake, it increases the availability of norepinephrine in synaptic spaces, which helps enhance mood regulation and emotional stability.
Reboxetine is not approved by the FDA in the United States but is available in Europe and other countries. Common side effects may include dry mouth, constipation, insomnia, sweating, and dizziness. Patients with certain heart conditions, epilepsy, or urinary problems should use caution. As with all antidepressants, it may take several weeks before full therapeutic effects are experienced, and discontinuation should be managed carefully under medical supervision.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy